Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

Open access
Lo Russo, Giuseppe, Moro, Massimo, Sommariva, Michele, Cancila, Valeria, Boeri, Mattia, Centonze, Giovanni, Ferro, Simona, Ganzinelli, Monica, Gasparini, Patrizia, Huber, Veronica, Milione, Massimo, Porcu, Luca, Proto, Claudia, Pruneri, Giancarlo, Signorelli, Diego, Sangaletti, Sabina, Sfondrini, Lucia, Storti, Chiara, Tassi, Elena, Bardelli, Alberto, Marsoni, Silvia, Torri, Valter, Tripodo, Claudio, Colombo, Mario Paolo, Anichini, Andrea, Rivoltini, Licia, Balsari, Andrea, Sozzi, Gabriella, Garassino, Marina Chiara·2019·Clinical Cancer Research

Abstract

Purpose: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI). Neither clinicopathologic features nor biological mechanisms associated with HP have been identified. Experimental Design: Among 187 patients with non–small cell lung cancer (NSCLC) treated with ICI at our institute, cases with HP were identified according to clinical and radiologic criteria. Baseline histologic samples from patients treated with ICI were evaluated by IHC for myeloid and lymphoid markers. T-cell–deficient mice, injected with human lung cancer cells and patient-derived xenografts (PDX) belonging to specific mutational subsets, were assessed for tumor growth after treatment with antibodies against mouse and human programmed death receptor-1 (PD-1). The immune microenvironment was evaluated by flow cytometry and IHC. Results: Among 187 patients, 152 were evaluable for clinical response. We identified four categories: 32 cases were defined as responders (21%), 42 patients with stable disease (27.7%), 39 cases were defined as progressors (25.7%), and 39 patients with HP (25.7%). Pretreatment tissue samples from all patients with HP showed tumor infiltration by M2-like CD163+CD33+PD-L1+ clustered epithelioid macrophages. Enrichment by tumor-associated macrophages (TAM) was observed, even in tumor nodules from immunodeficient mice injected with human lung cancer cells and with PDXs. In these models, tumor growth was enhanced by treatment with anti–PD-1 but not anti–PD-1 F(ab)2 fragments. Conclusions: These results suggest a crucial role of TAM reprogramming, upon Fc receptor engagement by ICI, eventually inducing HP and provide clues on a distinctive immunophenotype potentially able to predict HP. See related commentary by Knorr and Ravetch, p. 904

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-1390

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 408

Metadata

Authors
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., Milione, M., Porcu, L., Proto, C., Pruneri, G., Signorelli, D., Sangaletti, S., Sfondrini, L., Storti, C., Tassi, E., Bardelli, A., Marsoni, S., Torri, V., Tripodo, C., Colombo, M. P., Anichini, A., Rivoltini, L., Balsari, A., Sozzi, G., & Garassino, M. C.
Venue
Clinical Cancer Research
Published
2019-02-01
Volume
25
Issue
3
Pages
989-999
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2891951654
Cited by
408
References
31
FWCI
18.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1390
The paper
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., Milione, M., Porcu, L., Proto, C., Pruneri, G., Signorelli, D., Sangaletti, S., Sfondrini, L., Storti, C., Tassi, E., . . . Garassino, M. C. (2019). Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1390

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.